prikaz prve stranice dokumenta Šećerna bolest i inhibitori DPP IV/CD26
  Download
PDF 1.4 MB
Scientific paper - Review paper
Šećerna bolest i inhibitori DPP IV/CD26
Medicina Fluminensis, 55 (2019), 3; 200-214. https://doi.org/10.21860/medflum2019_221600
Batičić, Lara; Ivanović, Lara; Grčić, Antonijo; Pernjak Pugel, Ester; Varljen, Jadranka; Detel, Dijana

Cite this document

Batičić, L., Ivanović, L., Grčić, A., Pernjak Pugel, E., Varljen, J. & Detel, D. (2019). Šećerna bolest i inhibitori DPP IV/CD26. Medicina Fluminensis, 55. (3), 200-214. doi: 10.21860/medflum2019_221600

Batičić, Lara, et al. "Šećerna bolest i inhibitori DPP IV/CD26." Medicina Fluminensis, vol. 55, no. 3, 2019, pp. 200-214. https://doi.org/10.21860/medflum2019_221600

Batičić, Lara, Lara Ivanović, Antonijo Grčić, Ester Pernjak Pugel, Jadranka Varljen and Dijana Detel. "Šećerna bolest i inhibitori DPP IV/CD26." Medicina Fluminensis 55, no. 3 (2019): 200-214. https://doi.org/10.21860/medflum2019_221600

Batičić, L., et al. (2019) 'Šećerna bolest i inhibitori DPP IV/CD26', Medicina Fluminensis, 55(3), pp. 200-214. doi: 10.21860/medflum2019_221600

Batičić L, Ivanović L, Grčić A, Pernjak Pugel E, Varljen J, Detel D. Šećerna bolest i inhibitori DPP IV/CD26. Medicina Fluminensis [Internet]. 2019 [cited 2024 November 15];55(3):200-214. doi: 10.21860/medflum2019_221600

L. Batičić, L. Ivanović, A. Grčić, E. Pernjak Pugel, J. Varljen and D. Detel, "Šećerna bolest i inhibitori DPP IV/CD26", Medicina Fluminensis, vol. 55, no. 3, pp. 200-214, 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:756707. [Accessed: 15 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (croatian)Šećerna bolest i inhibitori DPP IV/CD26
Title (english)Diabetes mellitus and DPP IV/CD26 Inhibitors
AuthorLara Batičić
AuthorLara Ivanović
AuthorAntonijo Grčić
AuthorEster Pernjak Pugel
AuthorJadranka Varljen
AuthorDijana Detel
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Histology and Embryology)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Chemistry and Biochemistry)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Medical Biochemistry
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (croatian)
Šećerna bolest ili dijabetes (lat. diabetes mellitus) metabolička je bolest kronične naravi, karakterizirana perzistentnom hiperglikemijom te poremećajima u metabolizmu ugljikohidrata, masti i proteina. Bolest se dijeli na dijabetes tipa 1 i 2, gestacijski dijabetes te ostale, manje zastupljene oblike. Zbog velikog rasta incidencije i prevalencije bolesti, riječ je o značajnom javno-zdravstvenom problemu te jednom od deset vodećih uzroka smrtnosti u svijetu. Dipeptidil-peptidaza IV, odnosno molekula CD26 (DPP IV/CD26, EC 3.4.14.5), ubikvitaran je multifunkcionalan transmembranski i solubilni glikoprotein te serinska peptidaza, prepoznat kao krucijalan čimbenik u održavanju homeostaze glukoze u krvi, prije svega zbog mogućnosti razgradnje inkretina. Znanstvena i klinička ispitivanja ukazala su na visok terapijski potencijal inhibitora enzimske aktivnosti DPP IV/CD26 kod oboljelih od dijabetesa. Ovaj se pregledni rad fokusira na različite aspekte dijabetesa tipa 1 i 2 te novije mogućnosti terapije ovih oboljenja, s posebnim osvrtom na inhibitore DPP IV/CD26 kao efikasne terapijske opcije.
Abstract (english)
Diabetes (lat. Diabetes mellitus) is a chronic metabolic disease characterized by persistent hyperglycaemia and carbohydrate, fat and protein metabolism disorders. Diabetes could be classified as type 1 or 2, gestational diabetes, and other, less common forms. Due to a prominent increase in the incidence and prevalence of the disease, it represents a significant public-health problem, being between the ten leading causes of mortality in the world. Dipeptidyl peptidase IV, or molecule CD26 (DPP IV / CD26, EC 3.4.14.5), is an ubiquitous multifunctional transmembrane and soluble glycoprotein and serine peptidase, recognized as a crucial factor in maintaining glucose homeostasis, primarily due to the ability to hydrolize incretins. Scientific and clinical studies have shown a high therapeutic potential of DPP IV/CD26 inhibitors in diabetic patients. This review focuses on various aspects of type 1 and 2 diabetes and newer treatment approaches for these diseases, with a special focus on DPP IV/CD26 inhibitors as effective therapeutic options.
Keywords (croatian)
Keywords (english)
Languagecroatian
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMedicina Fluminensis
Numberingvol. 55, no. 3, pp. 200-214
p-ISSN1847-6864
e-ISSN1848-820X
DOIhttps://doi.org/10.21860/medflum2019_221600
URN:NBNurn:nbn:hr:184:756707
Publication2019
ProjectNumber: 13.06.1.2.26
Title (croatian): Uloga proteina obitelji DPP IV u kroničnim bolestima
Leader: Jadranka Varljen
Jurisdiction: Croatia
Funding stream: Sveučilište u Rijeci
Document URLhttps://hrcak.srce.hr/221600
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2019-09-09 12:40:39